TCTMD

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

A high-profile study that purported to provide the first reassurances ACE inhibitors and ARBs could be safely used in the setting of COVID-19 continues to be cited long after it was retracted over concerns of scientific fraud, a new analysis shows.
Nasdaq

ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results

Interim analysis of the ACE-Breast-02 study being conducted by Ambrx’s partner, NovoCodex Biopharmaceuticals, was completed by the Independent Data Monitoring Committee (IDMC) The pivotal Phase 3 ACE-Breast-02 study met its pre-specified interim primary ...

Acerand reports first-in-human trial results for ACE-106 therapy

Acerand Therapeutics has reported updated findings from its first-in-human Phase I/II study ACE-106-001 of ACE-106 (ACE-86225106), targeting patients with advanced solid tumours. As of 5 February 2026, 57 patients with pretreatment histories, having undergone a median of three prior therapy lines, have been administered ACE-106.